PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34411643-7	2021	Furthermore, inhibition of sEH could ameliorate neuroinflammation, neuronal death, and oxidative stress via stabilizing the in vivo level of epoxyeicosatrienoic acids (EETs), especially 8,9-EET and 14,15-EET, further resulting in the anti-AD effect through the regulation of GSK3beta-mediated NF-kappaB, p53, and Nrf2 signaling pathways.	14,15-epoxy-5,8,11-eicosatrienoic acid	198-207	epoxide hydrolase 2, cytoplasmic	Mus musculus	27-30	
32973044-6	2020	14,15-EET levels in the brains of these mice were also increased by sEH inhibition.	14,15-epoxy-5,8,11-eicosatrienoic acid	0-9	epoxide hydrolase 2, cytoplasmic	Mus musculus	68-71	
32535385-6	2020	Moreover, soluble epoxide hydrolase (sEH) activity was detected by a 14, 15-EET/DHET ELISA kit.	14,15-epoxy-5,8,11-eicosatrienoic acid	69-79	epoxide hydrolase 2, cytoplasmic	Mus musculus	10-35	
32535385-6	2020	Moreover, soluble epoxide hydrolase (sEH) activity was detected by a 14, 15-EET/DHET ELISA kit.	14,15-epoxy-5,8,11-eicosatrienoic acid	69-79	epoxide hydrolase 2, cytoplasmic	Mus musculus	37-40	
31866410-4	2020	AUDA, a sEH inhibitor, was given daily for 9 weeks orally, which significantly increased the level of 14,15-EET by inhibiting the expression of sEH and increasing the expression of CYP2J2 in lung tissues.	14,15-epoxy-5,8,11-eicosatrienoic acid	102-111	epoxide hydrolase 2, cytoplasmic	Mus musculus	8-11	
31866410-4	2020	AUDA, a sEH inhibitor, was given daily for 9 weeks orally, which significantly increased the level of 14,15-EET by inhibiting the expression of sEH and increasing the expression of CYP2J2 in lung tissues.	14,15-epoxy-5,8,11-eicosatrienoic acid	102-111	epoxide hydrolase 2, cytoplasmic	Mus musculus	144-147	
23434473-3	2013	A novel, potent, selective inhibitor of recombinant human, rat and mouse sEH, GSK2256294A, exhibited potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET in human, rat and mouse whole blood in vitro, and a dose-dependent increase in the LTX/LTX diol ratio in rat plasma following oral administration.	14,15-epoxy-5,8,11-eicosatrienoic acid	187-196	epoxide hydrolase 2, cytoplasmic	Mus musculus	73-76	
25128026-4	2015	The substrate of sEH, 14,15-epoxyeicosatrienoic acid (14,15-EET), protected TH-positive cells and alleviated the rotarod performance deficits of wild-type mice but not sEH-knockout mice.	14,15-epoxy-5,8,11-eicosatrienoic acid	22-52	epoxide hydrolase 2, cytoplasmic	Mus musculus	17-20	
27488890-7	2016	The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P < 0.001) and 5.6-fold higher post-ischemia (P < 0.001) in sEH-/- compared with sEH+/+ mice.	14,15-epoxy-5,8,11-eicosatrienoic acid	4-13	epoxide hydrolase 2, cytoplasmic	Mus musculus	130-133	
27488890-7	2016	The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P < 0.001) and 5.6-fold higher post-ischemia (P < 0.001) in sEH-/- compared with sEH+/+ mice.	14,15-epoxy-5,8,11-eicosatrienoic acid	4-13	epoxide hydrolase 2, cytoplasmic	Mus musculus	151-154	
18835921-7	2008	14,15-EET, the main substrate for sEH, was administered intravenously 15 min before LCA occlusion or during ischemia 5 min before reperfusion.	14,15-epoxy-5,8,11-eicosatrienoic acid	0-9	epoxide hydrolase 2, cytoplasmic	Mus musculus	34-37	
18835921-13	2008	Strategies to increase 14,15-EET, including sEH inactivation, may represent a novel therapeutic approach for cardioprotection against myocardial ischemia-reperfusion injury.	14,15-epoxy-5,8,11-eicosatrienoic acid	23-32	epoxide hydrolase 2, cytoplasmic	Mus musculus	44-47